Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
FDA classifies prognostic test for preeclampsia development/progression into class II (special controls), establishing regulatory requirements for market clearance.
Aforeworn detected this change in the Healthcare AI Regulation (FDA / ONC) space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Manufacturers and developers of prognostic tests for preeclampsia, including those using AI/ML algorithms, seeking FDA clearance. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline stated; classification is effective upon publication (June 26, 2026). Existing devices must comply or face enforcement.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Healthcare AI Regulation (FDA / ONC) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The test is now classified as class II medical device, requiring premarket notification (510(k)) and compliance with special controls (e.g., clinical performance data, labeling, quality system regulations).
Who it affects
Manufacturers and developers of prognostic tests for preeclampsia, including those using AI/ML algorithms, seeking FDA clearance.
What you must do
Submit a 510(k) premarket notification with evidence meeting special controls before marketing the test.
Deadline
No specific deadline stated; classification is effective upon publication (June 26, 2026). Existing devices must comply or face enforcement.
Never miss a change like this again
Aforeworn watches Healthcare AI Regulation (FDA / ONC) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Healthcare AI Regulation (FDA / ONC)
- US-CONGRESS BILLS-119s5057is: Safeguarding Against Fabricated Exploitation Through Artificial Intelligence Act of 2026
- US-CONGRESS BILLS-119s4110rs: Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness for Health Act; EMPOWER for Health Act
- US-CONGRESS BILLS-119hr9917ih: AI Kill Switch Act
- Medical Devices; Radiology Devices; Classification of the Radiological Machine Learning-Based Quantitative Imaging Software With Predetermined Change Control Plan
- Medical Devices; Neurological Devices; Classification of the Computerized Behavioral Therapy Device for the Treatment of Fibromyalgia Symptoms